Company intelligence / Profile preview

Kowa Company, Ltd.

Ownership: Public · 7807
Employees: ~7974
Development stage: Commercial

Overview

Kowa Company, Ltd. is a diversified Japanese conglomerate with a major focus on pharmaceuticals and medical devices. Its pharmaceutical division has developed several globally marketed drugs—most notably Livalo® for dyslipidemia—and maintains active R&D programs in cardiometabolic and ophthalmic diseases. The company operates internationally with subsidiaries in the US, Europe, China, and Southeast Asia.

Therapeutic areas: OphthalmologyCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

18 assets

calcium polystyrene sulfonate

Approved

17 more assets in the full pipeline.

Request access →

Partnerships

Center for Interdisciplinary Cardiovascular Sciences at Brigham & Women’s Hospital/Harvard Medical School for translational cardiovascular research.

Beyond the preview

Go deeper on Kowa Company, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kowa Company, Ltd..

Explore the full profile